PathAI Announces Multi-Year Collaboration Agreement with Bristol Myers Squibb

PathAI (AI-powered pathology) entered into multi-year expanded collaboration agreement with Bristol Myers Squibb to focus on translational research in oncology, fibrosis, and immunology, with a goal to continue transitioning this work into clinical trials. Bristol Myers Squibb and PathAI will utilize AI pathology models to de-risk therapeutic development across the Bristol Myers Squibb’s pipeline by identifying patient populations, and to obtain key insights to help patient segmentation in clinical trials across multiple disease indications. The companies are also collaborating on developing AI-powered diagnostics, measuring CD8 T-cell infiltration across oncology disease areas. The existing collaboration between the companies began in 2016 and has shown results in multiple areas. In June 2020, PathAI and Bristol Myers Squibb presented retrospective exploratory findings from completed clinical trials on AI-powered PD-L1 scoring, which identified more patients as PD-L1 positive compared to manual-based PD-L1 scoring. In November 2021, the companies jointly presented results from PathAI’s CD8 algorithm at The Society for Immunotherapy of Cancer (SITC) Annual Meeting. In July 2022, the two companies jointly published new exploratory data in the Journal of Modern Pathology, comparing the use of AI-powered algorithms to manual IHC scoring PD-L1 expression in relation to outcomes across multiple cancer types from several clinical trials.